Anticancer vaccines have gained a new lease of life with techniques to personalise them to individual patients. Cutting edge developments in this re-energised field were revealed at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.
The original anticancer vaccines, launched in the late 1990s, were based on shared tumour antigens and failed to induce a potent immune response. After decades of disappointing results, a number of advances have sparked a renewed interest in the field. These include new technologies and prediction algorithms to personalise vaccines, and the introduction of check point inhibitors for combination therapy
Dr Michal Bassani-Sternberg, Group Leader, Immunopeptidomics, Hi-TIDe Laboratory, Department of Oncology, University of Lausanne, Switzerland, and the Ludwig Institute for Cancer Research in Lausanne, said: “The ‘Modern anticancer vaccines’ session at the ESMO Immuno-Oncology Congress was timely since there is again a flurry of activity around anticancer vaccines. We can now customise vaccines for each patient based on the genomic information in their tumour, and the early results are promising.”
Personalisation has been made possible with high-throughput next generation sequencing. This technology identifies mutations that are unique to a patient’s tumour and are not found elsewhere in the body, meaning that a vaccine mounts a local immune response. Algorithms can predict which neoantigens should be targeted for vaccination.
Bassani-Sternberg said: “We have a good way to fish out and propose targets for vaccination. The first trials were published last year and showed that the selected targets were immunogenic, meaning that vaccination induced immune responses or amplified existing immune responses against these neoantigens. In addition, the vaccines worked well with check point inhibitors. We now need to see if vaccination against neoantigens leads to tumour regression.”
Neoantigens were explored in a dedicated session at the ESMO Immuno-Oncology Congress and were discussed in the session on modern anticancer vaccines, which also described the role of other vaccine targets. These include oncogenic proteins such as HER2, pathogens like the human papilloma virus (HPV), and prostate-specific antigens. These shared antigens are also being tested in combination with check point inhibitors.
Bassani-Sternberg said the combination of modern anticancer vaccines and check point inhibitors appears to generate the most effective immune response. “Vaccines can induce new responses in patients with ‘cold tumours’ which lack immune cells, thus making the environment receptive to check point inhibitors,” she said.
Numerous questions remain unanswered, such as when to vaccinate patients. Should this be immediately after surgery, when there are few tumour cells left, or beforehand? Should vaccines be administered against primary tumours and metastases? Will it be necessary to give new vaccines every few months as tumours evolve naturally and in response to treatment? How and when should vaccines be combined with other therapies?
But despite these questions, vaccination appears feasible. The technology to develop vaccines is available and getting better, the vaccines are safe and immunogenic, and there is openness from the regulators to testing vaccines in clinical trials. Bassani-Sternberg said: “We are counting on new technologies that have now matured. Next generation sequencing has made identification of vaccine targets more efficient, reliable, and cheaper. The algorithms to interpret this data are benchmarked and validated for predicting which targets are most likely to be immunogenic. Sequencing technologies are only going to get better and prediction tools will become even more accurate.”
“There is great hope for vaccines,” she continued. “And they have the potential to benefit most patients because almost all tumours have targets that could be vaccinated.”
Learn more: Anticancer Vaccines Gain new Lease of Life with Personalisation Techniques
The Latest on: Personalized anticancer vaccines
[google_news title=”” keyword=”Personalized anticancer vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized anticancer vaccines
- Outlining Novel Cellular Adjuvant Products for Therapeutic Vaccines Against Canceron May 29, 2023 at 5:00 pm
Various adjuvant products are currently under evaluation as potential candidates for use in cancer vaccines. There are several anticancer developmental vaccines containing different adjuvants both ...
- After battling COVID, can mRNA vaccines fight cancer?on May 28, 2023 at 5:47 am
The pandemic put the technology, long in development, to the test. Here’s a look at the status of its application to cancer and when it might reach patients.
- Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01on May 26, 2023 at 11:58 am
Importantly, EVX-01 induced a broad immune response that correlated with clinical outcome, which is very encouraging for the further development of Evaxion’s personalized cancer vaccine programs ...
- Personalized mRNA Vaccine Could Be Used To Treat Pancreatic Canceron May 26, 2023 at 9:15 am
An NIH-funded research team led by Dr. Vinod Balachandran from Memorial Sloan Kettering Cancer Center (MSKCC) have been developing a personalized mRNA cancer-treatment vaccine approach. It is designed ...
- Personalized vaccine could help fight pancreatic canceron May 15, 2023 at 3:51 am
The reason it's personalized is that the vaccines are made in a way that each vaccine is unique to each patients with pancreatic cancer." They are made post surgery, the tumor is processed ...
- Could personalized neoantigen vaccines prevent the recurrence of pancreatic cancer and increase patient survival?on May 12, 2023 at 6:25 am
In a recent article published in Nature, researchers conducted a phase I clinical trial of a personalized messenger ribonucleic acid (mRNA) neoantigen vaccine based on uridine mRNA–lipoplex ...
- Pancreatic cancer vaccine may slow return of disease, trial showson May 11, 2023 at 1:39 pm
A gene-targeted personalized vaccine may delay the return of pancreatic cancer according to a small, but promising, trial. The mRNA vaccine, which was tailored to the genetic makeup of each ...
- Personalized mRNA vaccine to treat aggressive pancreatic cancer in clinical trialon May 11, 2023 at 6:29 am
However, PDAC is not one of them, though the team now reports that personalized vaccines might make such an approach viable. Immunotherapy works by inducing the immune system to attack tumors by ...
- An mRNA vaccine that programs the body to fight pancreatic cancer shows early promiseon May 11, 2023 at 12:05 am
She credits an experimental therapy – a personalized cancer vaccine – being tested by BioNTech, one of the companies that helped make the mRNA vaccines for Covid-19. Brigham was one of 16 ...
- Personalized mRNA Vaccines Offer Hope for Treating Pancreatic Canceron May 10, 2023 at 3:31 pm
Researchers at Memorial Sloan Kettering Cancer Center, BioNTech, and Genentech say they have developed individualized mRNA pancreatic cancer vaccines.
via Bing News